For people in the MetroWest region living with lung diseases such as chronic obstructive pulmonary disease (COPD), emphysema, ...
The global chronic disease management market size is estimated to be worth USD 5.57 billion in 2024 and is projected to reach ...
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved ...
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) Friday said the National Medical Products Administration (NMPA) in China has ...
The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary ...
Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...
The following is a summary of “Comparative Effectiveness of qSOFA, CURB-65, and PSI in Predicting Pneumonia Hospitalization ...
Denham Thomas, from Hartlepool, saw his life drastically altered by Chronic Obstructive Pulmonary Disease, becoming dependent ...
While smoking is a key risk factor for chronic obstructive pulmonary disease (COPD), significant prevalence also exists among ...
Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth ...
Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...
Regeneron and Sanofi on Friday said the green light covers Dupixent as an add-on maintenance treatment in certain adults with uncontrolled chronic obstructive pulmonary disease, or COPD, and makes ...